SOTYKTU was launched as a better oral treatment for plaque psoriasis than the incumbent Otezla. But HCPs didn’t necessarily see a need to switch from their oral go-to or carve out a niche for moderate patients not yet ready for powerful biologics.
We continuously developed and refreshed in-depth iVAs (and their briefcases) for different derm segments and practitioners, accounting for up to 5 separate tactics.